DeLLphi-305: OS-positive phase III.

Nurullah İlhan,MD· @drnurullahilhan · X·2026-10-25 05:02· 10 hours agoScore70

Body · original

After chemo + durvalumab without progression in ES-SCLC, adding maintenance tarlatamab improved OS:
21.1 vs 12.7 months; HR 0.42, P<0.001.

OS measured from maintenance randomization.

#DeLLphi305 #ESMO2026 #LCSM

3 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

Source: Nurullah İlhan,MD · x.com